title: Recurrent Glioblastoma: Where we stand.
abstract: Current first-line treatment regimens combine surgical resection and chemoradiation for Glioblastoma that provides a slight increase in overall survival. Age on its own should not be used as an exclusion criterion of glioblastoma multiforme (GBM) treatment, but performance should be factored heavily into the decision-making process for treatment planning. Despite aggressive initial treatment, most patients develop recurrent diseases which can be treated with re-resection, systemic treatment with targeted agents or cytotoxic chemotherapy, reirradiation, or radiosurgery. Research into novel therapies is investigating alternative temozolomide regimens, convection-enhanced delivery, immunotherapy, gene therapy, antiangiogenic agents, poly ADP ribose polymerase inhibitors, or cancer stem cell signaling pathways. Given the aggressive and resilient nature of GBM, continued efforts to better understand GBM pathophysiology are required to discover novel targets for future therapy.
authors.affiliation: Department of Radiotherapy, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
authors.forename: Sanjoy
authors.initials: S
authors.lastname: Roy
authors.affiliation: Department of Radiotherapy, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
authors.forename: Debarshi
authors.initials: D
authors.lastname: Lahiri
authors.affiliation: Department of Radiotherapy, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
authors.forename: Tapas
authors.initials: T
authors.lastname: Maji
authors.affiliation: Department of Radiotherapy, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
authors.forename: Jaydip
authors.initials: J
authors.lastname: Biswas
keywords: Chemotherapy; glioblastoma multiforme; glioma; targeted therapy; temozolomide